MiR-335 Inhibits Small Cell Lung Cancer Bone Metastases via IGF-1R and RANKL Pathways

Meng Gong\textsuperscript{1,2}, Junrong Ma\textsuperscript{1,2}, Ryan Guillemette\textsuperscript{2}, Mingliang Zhou\textsuperscript{1}, Yan Yang\textsuperscript{1}, Yujing Yang\textsuperscript{1}, Janet M. Hock\textsuperscript{2}, Xijie Yu\textsuperscript{1,2,*}

1. Laboratory of Endocrinology and Metabolism, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, P.R. China, 610041.


**Running Title:** Inhibition of Small Cell Lung Cancer Metastases by miR-355

**Conflict of interest statement**

Meng Gong, Junrong Ma, Ryan Guillemette, Mingliang Zhou, Yan Yang, Yujing Yang, Janet M. Hock and Xijie Yu declare that: we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled: “MiR-335 Inhibits Small Cell Lung Cancer Bone Metastases via IGF-1R and RANKL Pathways”

*Corresponding author:* Xijie Yu, MD, PhD
Address: Laboratory of Endocrinology and Metabolism, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, P.R. China;

Tel: +86-028-85422362;

Email: xijieyu@hotmail.com
Abstract

Small cell lung cancer (SCLC) is a rapidly progressing, incurable cancer that frequently spreads to bone. New insights are needed to identify therapeutic targets to prevent or retard SCLC metastatic progression. Human SCLC SBC-5 cells in mouse xenograft models home to skeletal and non-skeletal sites while human SCLC SBC-3 cells only pervade non-skeletal sites. Because microRNAs (miRNAs) often act as tumor-regulators, we investigated their role in preclinical models of SCLC. miRNA expression profiling revealed selective and reduced expression of miR-335 and miR-29a in SBC-5 cells, compared to SBC-3 cells. In SBC-5 cells, miR-335 expression correlated with bone osteolytic lesions while miR-29a expression did not. Over-expression of miR-335 in SBC-5 cells significantly reduced cell migration, invasion, proliferation, colony formation, and osteoclast induction in vitro. Importantly, in miR-335 over-expressing SBC-5 cell xenografts (n=10), there were minimal osteolytic lesions in the majority of mice and none in three mice. Expression of RANKL and IGF-1R, key mediators of bone metastases, were elevated in SBC-5 as compared to SBC-3 cells. Mechanistically, over-expression of miR-335 in SBC-5 cells reduced RANKL and IGF-1R expression. In conclusion, loss of miR-335 promoted SCLC metastatic skeletal lesions via de-regulation of IGF-1R and RANKL pathways and was associated with metastatic osteolytic skeletal lesions.

IMPLICATION STATEMENT: These preclinical findings establish a need to pursue the role of miR-335 in human SCLC with metastatic skeletal disease.

Key words: small cell lung carcinoma (SCLC), miR-335, bone metastasis, IGF-1R, RANKL
Introduction

Small cell lung cancer (SCLC), a highly aggressive form of lung cancer associated with tobacco smoking (1-2), represents 10-15% of all lung cancers (3-4). Treatment is challenging because SCLC grows rapidly, often becoming well established in lung before becoming symptomatic; metastatic spread occurs early and rapidly (5-6). For patients with localized or regionalized SCLC, 5-year survival in the US in 2008 was 52% and 25% respectively (7). For those who suffer metastatic SCLC or relapse, the prognosis is worse. Although there have been advances in therapy for localized SCLC with the introduction of positron emission tomography (PET), SCLC mortality has remained unchanged over the past 30 years (6).

Compared to our knowledge of skeletal metastases in breast and prostate cancers, we know very little about cell and molecular mechanisms of skeletal metastases in lung cancer, especially in SCLC. In osteolytic lesions, such as those in breast cancer, bone loss predominates, while increased bone turnover in which both bone formation and bone resorption are deregulated, is characteristic of skeletal metastases in prostate cancer (8-9). Over one third of patients with SCLC develop osteolytic bone metastasis, resulting in severe pain, pathologic fractures, spinal cord compression and loss of mobility to greatly reduce quality of life (10-11). Because of the lack of therapeutic options in SCLC, there is an urgent need to better understand how skeletal progression in SCLC may be controlled and treated.

MicroRNAs (miRNAs) critically regulate tumorigenesis and progression by targeting oncogenes, tumor suppressor genes, or genes related to proliferation, angiogenesis, and apoptosis. MiRNAs are a class of small non-coding RNAs of about 19-25 nucleotides (nt) that function as negative post-transcriptional gene regulators (12-13). By hybridizing to the 3’
untranslated region (UTR) of target mRNAs, miRNAs can serve as mediators of mRNA cleavage and cause translational repression, or act on transcription to reduce protein output by destabilizing mRNAs (14). Different tumor types and tumors at various differentiation stages may exhibit unique miRNA profiles (15). In non-small cell lung cancer (NSCLC) cells, miR-494, miR-30a, miR-193b, miR-101, miR-7, and miR-206 have been reported as tumor inhibitors (16-21), while miR-212 is believed to promote carcinogenesis in vitro (22). In NSCLC patients, high miR-155 and low let-7a-2 expression in tumor tissue have been reported to correlate with poor survival (23). Unfortunately, miRNAs which have been associated with clinical outcomes in metastatic NSCLC have not been found relevantly to SCLC (24). More research is needed to investigate the selectivity and specificity of miRNA pathways in SCLC and its metastatic spread to bone, and their possible value as therapeutic targets to improve survival.

Human SBC-5 and SBC-3 cell lines were originally established from human SCLC, and found to differ in their predilection for bone when tested as xenografts in immunodeficient mice (25-26). Xenografts of SBC-5 or SBC-3 cells formed multiple tumor foci in liver, pancreas, ovary/uterus, and kidney in NK (natural killer cell)-depleted immunodeficient mouse models. SBC-5 cell xenografts promoted osteolytic bone lesions, while SBC-3 cell xenografts did not (25-26). We previously reported a more consistent immunodeficient mouse host model for xenografts of bone metastases, using human SCLC SBC-5 cells injected into the tail vein of NOD-SCID IL2Rγnull mice, deficient in T cells, B cells and NK cells (27). SBC-5 and SBC-3 xenografts homed to multiple non-skeletal tissues, such as liver, pancreas, uterus, ovary and kidney, and formed lesions that were indistinguishable in location and
morphology (27). Osteolytic bone lesions were observed throughout the skeleton of mice with SBC-5 cell xenografts, while no bone lesions were observed in mice with SBC-3 cell xenografts (27). We applied this model to study skeletal progression of SCLC in the preclinical studies reported here.

Our goal was to investigate miRNAs involved in the regulation of skeletal metastatic SCLC lesions. A comparison of miRNA profiles of SBC-5 and SBC-3 cell lines revealed selective down-regulation in miR-335 and miR-29a in SBC-5 cells. Over-expression of miR-335, but not miR-29a, in SBC-5 cells decreased cell proliferation, colony formation, migration and invasion, and osteoclast induction in vitro, and prevented or reduced osteolytic metastases in vivo.
Materials and methods

Ethics statement

This study was approved by the Ethics Committees of West China Hospital of Sichuan University (China). Experiments in the US involving mice were reviewed and approved by The Jackson Laboratory Institutional Animal Care and Use Committee.

Cell culture

Human SCLC SBC-5 and SBC-3 cell lines (SBC-5 and SBC-3, respectively) were obtained from the Japan Health Sciences Foundation, Health Science Resources Bank (HSRB; JCRB0819 and JCRB0818), and authenticated by DNA short tandem repeats (STR) profile assay. SBC-5 and SBC-3 were maintained in Advanced DMEM medium (Invitrogen, Grand Island, NY) supplemented with 10% FBS (Thermo-Hycclone, Logan, UT). Human kidney cell line 293TN was purchased from SBI (System Biosciences, Mountain View, CA) and maintained in Advanced DMEM medium with 10% FBS.

Analysis of miRNA expression by microarray and qRT-PCR

RNA was extracted from cells using an RNeasy miRNA kit (Qiagen Inc., Valencia, CA). MiRNA microarrays were performed by LC Sciences (Houston, TX). The miRNA microarrays included 833 human miRNAs, representing miRNA transcripts listed in Sanger miRBase Release 11.0. The microarrays included four independent RNA samples from each cell line. To ensure accuracy of the hybridizations, each RNA sample was hybridized with three membranes. Hybridization signals for each spot of the array and background values at
15 empty spots were measured. Hybridization signals that failed to exceed the average background value by more than three standard deviations were excluded from analysis. Signal intensities for each spot were calculated by subtracting the background values from the total intensities. Data normalization was performed using positive control RNA spots (tRNA(G), tRNA(L), tRNA(T), tRNA(H) and 5S rRNA) to allow comparisons among chips. The remaining data were averaged among triplicate arrays, and the resulting four data sets, each corresponding to an RNA sample, were considered independent measurements for the purposes of paired, two-sample t test when comparing miRNA profiles in SBC-5 with SBC-3. Reverse transcriptase (RT) and quantitative real-time PCR were performed in a two-step reaction using Taqman miRNA assays according to the protocol provided by the manufacturer (Applied Biosystems, Foster City, CA). U6 was used as the internal control. The $2^{-\Delta\Delta CT}$ method described by Livak and Schmittgen (28) was used to analyze the data.

**Stable overexpression of miR-335 or miR-29a in the SBC-5 cell line**

A lentiviral expression system was used to establish stable SBC-5 cell lines with high miR-335 or miR-29a expression. Lenti-miR-335 or Lenti-miR-29a miRNA Precursor Expression Construct (System Biosciences, Mountain View, CA) was used to prepare lentivirus with the LentiSuite (System Biosciences, Mountain View, CA) according to the manufacturer’s protocol. The pGreenPuro Scramble Hairpin Control Construct (System Biosciences, Mountain View, CA) was used to prepare control lentivirus. Lentiviral infection was performed according to the manufacturer’s protocol. Transfected cells were trypsinized, diluted in culture medium and seeded in 96-well plate at one cell/well in average. After 7-day
culture, single cell colonies with high fluorescence were chosen out and cultured to be stable cell lines. qRT-PCR was used to assay the expression of miR-335 or miR-29a in these stable cell lines. The SBC-5 cell lines with highest miR-335 expression (named as SBC-5 miR-335+) or miR-29a expression (named as SBC-5 miR-29a+) were selected for the assays described in the following sections. SBC-5 cells transfected with control lentivirus was used as control cell line (named as SBC-5 VectorCtrl) for \textit{in vitro} and \textit{in vivo} experiments.

\textit{Cell migration and invasion}

SBC-5 miR-335+, SBC-5 miR-29a+ and SBC-5 VectorCtrl cell lines were serum-starved for 24h, trypsinized and resuspended in 0.1% FBS-supplemented medium with no additional growth factors. SBC-5 cells were plated at a density of $1 \times 10^4$ cells/well in a transwell insert (3 \(\mu\)m pore size, BD Biosciences, San Jose, CA) for the migration assay, and in a matrigel-coated, growth-factor-reduced, invasion chamber (8 \(\mu\)m pore size, BD Biosciences, San Jose, CA) for the invasion assay. 10% FBS-containing medium was added into 24-well plates to provide a chemoattractant. After 6h incubation for the migration assay, or after 22h incubation for the invasion assay, cells were fixed with 4% paraformaldehyde for 1h. Cells on the apical side of each insert were removed by mechanically scraping. Cells located on the basal side of the membrane were stained with 0.1% crystal violet, and visualized under a Zeiss Axiovert 200M microscope. Cell numbers were quantified using Metamorph analysis software.

\textit{MTT proliferation assay}
SBC-5 miR-335\(^{+}\), SBC-5 miR-29a\(^{+}\) and SBC-5 Vector\(^{\text{Ctrl}}\) cell lines were cultured to 70-80% confluence, serum-starved for 24h, and then cultured at a density of 1,500 cells/well in 96-well plates with advanced DMEM medium supplemented with 2% FBS at 5% CO\(_2\), 37\(^\circ\)C. At selected time points, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added at a final concentration of 0.5mg/ml. After 4h incubation at 37 \(^\circ\)C, medium was removed and purple blue sediment was dissolved in 150 \(\mu\)L of DMSO. The relative optical density (OD) for each well was determined using a Wellscan MK3 ELISA kit (Labsystems, Dragon, Finland) as a measure of proliferation.

*Colony formation*

SBC-5 miR-335\(^{+}\), SBC-5 miR-29a\(^{+}\) and SBC-5 Vector\(^{\text{Ctrl}}\) cell lines were seeded at a density of 100 cells/dish in 60-mm dishes, and cultured for 14 days. Cells were fixed with 4% paraformaldehyde for 20 minutes, and stained with 0.1% crystal violet for 30 min. Colony numbers were counted using bright-field microscopy.

*Osteoclast induction assay, using SBC-5 conditioned media*

SBC-5 miR-335\(^{+}\), SBC-5 miR-29a\(^{+}\) and SBC-5 Vector\(^{\text{Ctrl}}\) cell lines were cultured to 90% confluence, washed with PBS and incubated at 37\(^\circ\)C for 24h in advanced DMEM medium with 0.5 \% FBS. Incubation supernatants from each SBC-5 cell line were harvested and conditioned media (CM) were prepared as 10% incubation supernatant, 10\% FBS, 80\% \(\alpha\)-MEM, 10ng/ml M-CSF and 10ng/ml RANKL for each cell line. Cell-free unconditioned medium (UM) was constituted as 90\% \(\alpha\)-MEM with 10\% FBS, 10ng/ml M-CSF and 10ng/ml
RANKL. For osteoclast induction assays, spleen cells from 4-week old C57BL mice (strain: C57BL/6J, Jackson Laboratory, Bar Harbor, ME) were prepared, using the method described by Granholm S.P. et al (29). The cells were seeded in 24-well plate at $1 \times 10^7$/well, and cultured in conditioned or unconditioned media. Cells were cultured for 7 days, with media replaced every 2 days. On the final day, cells were fixed in 4% paraformaldehyde and stained for TRAP (Tartrate-Resistant Acid Phosphatase) using Acid Phosphatase, Leukocyte (TRAP) Kit (Sigma-Aldrich, St Louis, MO). TRAP$^+$ cells with 3 or more nuclei were counted under brightfield microscopy, and expressed as number of osteoclasts/well.

**Western blotting**

Cells were lysed in RIPA buffer containing Halt Protease Inhibitor Cocktail (Pierce, Rockford, IL). Protein concentration was determined with Quick Start™ Bradford Protein Assay kit (Bio-Rad, Hercules, CA). The blotting membrane was incubated overnight at 4ºC with different primary antibodies: anti-IGF-1R (1:1000; Abcam, MA), anti-RANKL (1:500; Epitomics, CA) and anti-β-actin (1:1000; Sigma). The blots were incubated for 1h at room temperature with either horseradish peroxidase-conjugated secondary antibody: anti-mouse or anti-rabbit IgG (Chemicon, Temecula, CA). Signals were visualized using ECL plus chemiluminescence substrate (Amersham, Piscataway, NJ).

**RANKL 3' UTR reporter assay**

The potential miR-335 target site predicted by miRanda on RANKL mRNA 3’UTR was amplified from human genomic DNA using the primer pair (forward: 5'
GTCTGGAGAGGAAATCAGCATCGA-3′); reverse: 5′-TTCAGATGATCCTTCAATTGCGCT-3′) and sub-cloned into the pMIR-REPORT™ miRNA reporter vector (Ambion, Austin, TX). Recombined plasmids were confirmed by DNA sequencing. Point mutation within the target sequence for miR-335 in 3′UTR (3′UTRm) was generated by the QuickChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, TX) using primers (forward: 5′-TATCCATAAGGTTGACCTTGTAGAGAACGCGTAT-3′ and 5′-AAGGTCAACCTTATGGATACTGAGTCGTGTACCGT-3′). The plasmid containing 3′UTRm was sequenced to confirm replacement of the targeted residues. Lentivirus was used to stably transfect miR-335 precursor gene or control sequence into 293TN cells. Transfected cells were further co-transfected via a pMIR reporter vector with RANKL 3′UTR fragment, or corresponding mutation fragment together with the pMIR-REPORT™ beta-galactosidase reporter control vector (Ambion, Austin, TX). Cells were collected at 24 h after transfection. The ratio of beta-galactosidase to firefly luciferase was measured with Dual Luciferase Assay kit (Promega, Madison, WI).

SCLC skeletal metastases model

Immunodeficient mice, NOD-SCID IL2Rγnull (strain: NOD.Cg-Prkdcscid Il2rγtm1Wjl/SzJ; Jackson Laboratory, ME), were housed as 2-5 same sex mice in polycarbonate cages (324 cm²) at The Jackson Laboratory research laboratory under barrier conditions. Mice were maintained under 14:10-hr light: dark cycles; provided sterilized White Pine shavings for bedding, and fed with NIH 31 irradiated diet (6% fat, 19% protein, Ca:P of 1.15:0.85), with
vitamin and mineral fortification (Purina Mills International, Brentwood, MO), and sterilized water ad libitum.

SBC-5 miR-335+, SBC-5 miR-29a+ and SBC-5 VectorCtrl were cultured under equivalent conditions. Cells were harvested at about 80% confluence, washed with ice-cold PBS twice, and re-suspended in cold PBS at a density of $5 \times 10^6$ cells/ml. On day 0, the cell suspension was injected at $1 \times 10^6$ cells per mouse via tail vein injection into 8-week old NOD-SCID IL2Rγnull male mice (10 mice per group). Mice were euthanized on day 28, and their bodies were fixed in 10% neutralized formalin for at least 2 days. Radiographs of the skeleton were taken with a Faxitron MX20 cabinet X-ray (Faxitron X-Ray Corp., Wheeling, IL) and Kodak Min-R 2000 mammography film (Eastman Kodak Co., Windsor, CO). Skeletal osteolytic lesions observed in radiographs were counted in the spine and right and left femurs, tibias and ulnar bones.

Statistical analyses

Analyses were performed with JMP 8.0 software (SAS, Cary, NC). We used ANOVA to compare multiple groups, followed by pairwise comparisons if significant differences were detected. Tukey–Kramer test was used for comparisons with a control group. Dunnett’s test was used to compare all groups. Unpaired t-tests were used to compare data when only two groups were used. Differences were considered statistically significant at $P < 0.05$ on a two-tailed test. Data were expressed as means ± standard error of the mean (SEM).
Results

Reduced expression of miR-335 and miR-29a in SBC-5 cells compared to SBC-3 cells

Prior work reports that SBC-5 cells colonize skeletal and non-skeletal tissues, while SBC-3 cells only colonize non-skeletal tissues. This fact indicates that SBC-5 cells may produce specific factors to communicate with osteoclasts and/or osteoblasts to colonize into skeleton. Indeed a few factors, such as PTHrP and CCR4 have been reported to be up-regulated in SBC-5 cells (30-31). The molecular mechanisms under up-regulation of these factors are not clear. miRNAs function as negative post-transcriptional gene regulators, we hypothesize that selective and specific miRNAs are expressed reductively in SBC-5 cells, which induce up-regulation of the bone communicating factors. In the primary screen, 14 miRNAs, including miR-9, miR-10a, miR-17-92 family, miR-29 family and miR-335, were expressed at lower levels in SBC-5 than in SBC-3 (fold-change >2, p-value <0.001) (Table 1 and Supplementary material, Fig. S1). Because microarray data reflects relative differences in miRNA expression patterns of SBC-5 and SBC-3, we determined if candidate miRNAs were also present in human normal lung tissues. Compared to normal lung tissue, miR-335 and miR-29a expression was lower in SBC-5 cells, while no changes were observed for the other miRNAs. Based on these observations, we focused on miR-335 and miR-29a and excluded the other miRNAs (Fig. 1).

Over-expression of miR-335, but not miR-29a, reduces in vitro carcinogenesis

Using a lentiviral transfection strategy, miR-335 or miR-29a genes were stably transfected into SBC-5 respectively. The lentivirus system enabled external miRNA gene expression from the constitutive CMV promoter and contained copGFP as a reporter. Lentiviral
transfection of SBC-5 was successful, exhibiting a robust transfection rate (>90%). To obtain stable cell lines with high expression of the selected miRNA, we screened GFP expression in single-colonies in 96-well plates, and verified miRNA expression by qRT-PCR. Transfection of miR-335 gene in SBC-5 (SBC-5 miR-335+) increased miR-335 expression by over 2600-fold, compared to control lentivirus transfected SBC-5 (SBC-5 VectorCtrl), that expressed very little miR-335 (Fig. 2A, P<0.001). SBC-5 expressed miR-29a at relatively high levels. Transfection of miR-29a gene in SBC-5 increased miR-29a expression only by approximately 4-fold compared to controls (Fig. 2B, P<0.001).

In migration and invasion assays *in vitro*, miR-335 over-expression in SBC-5 miR-335+ reduced cell migration by ~52% (average cell number per well, SBC-5 miR-335+: 687±77 vs. SBC-5 VectorCtrl: 1416±107. P<0.01. Fig. 2C) and cell invasion by ~46% (average invasive cell number per well, SBC-5 miR-335+: 86±9 vs. SBC-5 VectorCtrl: 159±21. P<0.05. Fig. 2D). In colony formation assay, because of metastatic nature, SBC-5 cells adhere poorly to plastic and proliferating cells often drift away from their original colonies to form additional colonies, so SBC-5 colony number usually exceeds the number of cells plated after 2-week culture. MiR-335 over-expression in SBC-5 miR-335+ reduced cell colony formation by ~48% (average colony number per dish, SBC-5 miR-335+: 168±10 vs. SBC-5 VectorCtrl: 322±11, P<0.001, Fig. 2E). In contrast, cell migration, cell invasion and colony formation of SBC-5 miR-29+ did not differ significantly from SBC-5 VectorCtrl (Fig. 2C-E). Compared to SBC-5 VectorCtrl, SBC-5 miR-335+ exhibited significantly lower proliferation from culture on day 3, while proliferation of SBC-5 miR-29a+ did not differ from SBC-5 VectorCtrl, except for a slight increase on days 3 and 4 of culture (Fig. 2F). Collectively, these data suggested that
miR-335 over-expression reduced the potential for metastatic cancer progression by inhibiting cell migration, invasion, proliferation and colony formation. In contrast, miR-29a over-expression did not modify key aspects of SBC-5 functional phenotype.

*Xenografts of SBC-5 miR-335+, but not SBC-5 miR-29a+, abrogated skeletal lesions in vivo*

“Metastatic” spread to skeletal and non-skeletal tissues was observed following intravenous tail injections of SBC-5 Vector\textsuperscript{Ctrl} xenograft. Radiographs showed SBC-5 Vector\textsuperscript{Ctrl} xenografts induced osteolytic bone lesions in the spine and long bones. In mice with SBC-5 miR-335\textsuperscript{+} xenografts, skeletal osteolytic lesions were absent in 3 mice and reduced overall (average number of lesions/mouse: 1.3±0.36 vs SBC-5 Vector\textsuperscript{Ctrl}: 3.3±0.42, P<0.01, Fig. 3). Four mice with either SBC-5 miR-335\textsuperscript{+} or SBC-5 miR-29a\textsuperscript{+} xenografts each exhibited 1 osteolytic lesion, while the remaining 3 mice with miR-335\textsuperscript{+} xenografts exhibited 3 osteolytic lesions each. Mice with SBC-5 miR-29a\textsuperscript{+} or Vector\textsuperscript{Ctrl} xenografts exhibited 2 or more (3-5) lesions each, in 6 and 9 mice, respectively (Fig. 3C). The number of osteolytic lesions developed by SBC-5 miR-29a\textsuperscript{+} xenografts did not differ significantly from SBC-5 Vector\textsuperscript{Ctrl} xenografts (average number of lesions/mouse: 2.3±0.45 vs SBC-5 Vector\textsuperscript{Ctrl}: 3.3±0.42, P>0.05, Fig. 3).

*Down regulation of IGF-1R in SBC-5 miR-335*

We used informatics prediction software (miRanda) to identify IGF-1R as a potential target of miR-335. Published literature confirmed that IGF-1R was a direct target of miR-335 (32), and its expression correlated with enhanced proliferation, invasion and migration ability in tumor cells (33-34) and bone metastases in breast and prostate cancers (35-36). Western-blotting
result showed SBC-5 expressed much higher IGF-1R than SBC-3 cells. In SBC-5 miR-335+,
but not in SBC-5 miR-29a+, IGF-1R expression was significantly less than that in SBC-5 VectorCtrl (Fig. 4).

*Down-regulation of osteoclast induction and RANKL expression in SBC-5 miR-335+, but not in SBC-5 miR-29a*. 

First, we assessed the effect of conditioned media (CM) from genetically modified SBC-5 cell lines on osteoclast induction in vitro. SBC-5 VectorCtrl CM, increased osteoclast numbers significantly compared to cell-free unconditioned medium (UM) (average osteoclast number per well, SBC-5 VectorCtrl CM: 67.2±5.6 vs cell-free UM: 20.7±3.8 in, P<0.001) (Fig. 5A-B). Compared to SBC-5 VectorCtrl CM, osteoclast induction was reduced by ~57% in SBC-5 miR-335+ CM (average 28.7±1.8 osteoclasts per well, P<0.001) and by 24% in miR-29a+ CM (average 49.5±4.8 osteoclasts per well, P<0.05).

Using miRanda software, we identified RANKL, a key cytokine regulating osteoclastogenesis, as a candidate target for miR-335. We found that RANKL expression was higher in cell lysates and culture medium of SBC-5, than that in SBC-3. We confirmed that RANKL expression was significantly reduced in SBC-5 after over-expression of miR-335 (SBC-5 miR-335+), while RANKL expression was not different from controls in SBC-5 after over-expression of miR-29a (SBC-5 miR-29a+) (Fig. 5C). To demonstrate selectivity of RANKL by miR-335, RANKL 3′ UTR was cloned and placed within the 3′ UTR of a luciferase reporter expression cassette. Co-transfection in 293TN cells with either the miR-335 expression vector or a control vector showed that miR-335 over-expression
significantly reduced luciferase activity of the construct containing the target site of RANKL 3′UTR. When the target sequence was mutated, miR-335 failed to reduce luciferase activity (Fig. 5D-E). These data support the hypothesis that the abrogation or reduction of skeletal osteolysis by SBC-5 miR-335+ xenografts may be attributed in part to inhibition of RANKL expression. Collectively, our data support a role for miR-335, but not miR-29a, in the homing of human SCLC SBC-5 cells to bone.
Discussion

Very little is known of the cell and molecular mechanisms underlying the metastatic spread to the skeleton in SCLC. Preclinical studies suggest a role for deregulation of bone turnover because mouse xenograft models of SCLC-induced bone metastases are responsive to bisphosphonate drugs, such as zolendronate, which blunt bone resorption and slow bone turnover (37). Despite their efficacy, bisphosphonates in cancer patients have been linked to complications such as osteonecrosis of the jaw and bone fractures (38), creating a need for alternate therapies. To investigate alternate molecular regulators of the metastatic spread of SCLC cells to bone, we studied miRNA profiles using human SCLC SBC-5 and SBC-3 cell lines and xenografts in immunodeficient NOD-SCID IL2Rγnull mice, and identified miR-335 as putative candidate regulator of RANKL, a key cytokine regulating resorption, and skeletal osteolysis. Confirming the importance of miR-335 as a candidate regulator in metastatic progression, in vitro work by others showed that miR-335 over-expression in malignant breast cancer cell xenografts suppressed spread of breast cancer cells to lung and bone (39). Taken together with data in the present study, we hypothesize that miR-335 may be an important regulator of bone metastasis. The work reported here is the first to associate miR-335 with human SCLC, and to link miR-335 with bone metastases of SCLC.

Deregulation of miRNAs has been implicated in carcinogenesis, and miRNAs are being investigated as candidate oncology therapeutic targets for several different types of tumors (40-41). Multiple loci on chromosome 7 have been previously identified in genetic research on human lung cancer (42), so it is interesting that miR-335 is located in chromosome 7q32.2. In various metastatic breast cancer cell lines, gene deletion and epigenetic promoter
hypermethylation of the miR-335 locus on 7q32.2 appeared to be a common feature, resulting in the designation of miR-335 as a “selective metastasis suppressor and tumor initiation suppressor locus in human breast cancer” (43). In breast cancer, expression of miR-335 activated the tumor suppressor gene BRCA1 via effects on BRCA1 repressor ID4, resulting in increased apoptosis by down-regulation of ERα and IGF-1R (32). In gastric cancer cell lines, miR-335 targeted Bcl-w and specificity protein 1, both of which have also been linked to metastatic progression (44). Our data strongly suggests increased miR-335 may mitigate human metastatic SCLC, but clinical research is needed to validate this speculation, and to determine if there are common mechanisms regulated by miRNA across cancer types.

We speculated that miR-335 might target cytokines linked to osteoclast induction and bone turnover. We report two cytokines, IGF-1R and RANKL, both of which have been linked to metastases of other cancers (33-34), were expressed more highly in SBC-5 cells, and were regulated by miR-335. Deregulated IGF-1R may interact with ligand IGFs to stimulate proliferation, invasion, and migration and inhibit apoptosis of cancer cells (33). Breast cancer research has shown that bone-derived IGF-1 regulates interactions between bone and breast cancer cells via activation of the IGF-1R/Akt/NF-κB pathway and that IGF-1R knockdown significantly reduced xenograft-induced bone metastases (35). Extending the literature on breast cancer to SCLC, we now show down-regulation of IGF-1R in SBC-5 miR-335+ correlated with decreased cell proliferation, migration, invasion and colony formation.

RANKL regulates osteoclast induction, differentiation, survival and activation (36, 45) and has been implicated in cancer mechanisms (46). Breast cancer and melanoma cell xenografts migrating to bone may stimulate osteoclast differentiation by RANKL to
deregulate bone turnover, resulting in bone resorption and osteolysis (36, 46). Blocking RANKL markedly reduced tumor burden in bones (47). We extending previous reports in breast cancer and lung cancer literature by showing that down-regulation of RANKL in SBC-5 miR-335+ markedly reduced osteoclast induction, and that miR-335+ abrogated or reduced skeletal osteolysis induced by miR-335+ xenografts.

Development of NOD-SCID IL2Rγnull mice, which lack mature T cells, B cells and functional NK cells, as xenograft hosts greatly improved the predictability of human tumor xenograft phenotyping for cancer research (48). Using these mice, we reported skeletal osteolysis was induced within one month of placing SCLC SBC-5 xenografts. SBC-5 miR-335+ abrogated osteolysis in 3 of 10 mice, and markedly reduced the sites of osteolysis in remaining mice, while SBC-5 miR-29a+ had no such effect. These outcomes support our hypothesis that miR-335, but not miR-29a, appears a selective and specific suppressor of bone metastases in this model of small cell lung cancer. Our in vitro and in vivo experiments suggest miR-335 may be a candidate therapeutic target to mitigate bone metastases in SCLC. Clinical research will be necessary to validate this exciting possibility.

Funding

This work was support by grants from the National Natural Science Foundation of China [No. 81072190 to X Yu, No. 30900244 to M Gong, No. 81101920 to J Ma]; Science &Technology Department of Sichuan Province [2010SZ0168 to X Yu], the Ministry of Education of the People Republic of China ([2011]1139 to X Yu), Sichuan University [2011SCU04B42 to X
Yu] and US Army Medical Research and Materiel Command research contract USAMRMC[ No. 0704400], PI: JM Hock.
References


31. Miki T, Yano S, Hanibuchi M, Kanematsu T, Muguruma H, Sone S. Parathyroid hormone-related protein


42. Campbell J, Lockwood WW, Buys TP, Chari R, Coe BP, Lam S, et al. Integrative genomic and gene


Figure legends

Figure 1. Comparison of miR-335 and miR-29a expression in human SCLC SBC-5 and SBC-3 cells. Validation of miR-335 and miR-29a by qRT-PCR confirmed the miRNA array profiles as both miRNAs were significantly lower in SBC-5 cell, than in SBC-3 or in normal human lung tissue (***: P<0.001; n=5/group).

Figure 2. Over-expression of miR-335, but not miR-29a, reduces in vitro carcinogenesis.

A and B: Stable transfection of SBC-5 cells to over-express miR-335 or miR-29a was achieved using a lentiviral system. Screening of single colonies by qRT-PCR was used to select cell lines with the highest expression of miR-335 (SBC-5 miR-335+) or miR-29a (SBC-5 miR-29a+) (n=3/group) for subsequent studies. Stable SBC-5 cell line transfected with control lentivirus was used as control cell line (SBC-5 VectorCtrl). C and D: Compared to SBC-5 VectorCtrl cells, cell migration and invasion were significantly reduced in SBC-5 miR-335+ cells, but not in SBC-5 miR-29a+ cells (n=3/group, 2 replicate experiments). E: SBC-5 miR-335+ formed fewer colonies than SBC-5 VectorCtrl, while SBC-5 miR-29a+ was equivalent to SBC-5 VectorCtrl (n=3/group, 2 replicate experiments). F: Proliferation, assessed by the MTT assay, was lower in SBC-5 miR-335+ than that in SBC-5 VectorCtrl, while proliferation of SBC-5 miR-29a+ cells was equivalent or slightly increased compared to SBC-5 VectorCtrl cells (n=5/group/time point, 3 replicate experiments).

(Compared to control, *: P<0.05; **: P<0.01; ***: P<0.001).

Figure 3. SBC-5 miR-335+ xenografts abrogated completely, or in part, skeletal
osteolytic lesions in humanized NOD-SCID IL2Rγnull immunodeficient mice. SBC-5 miR-335+ cells, SBC-5 miR-29a+ cells or control (SBC-5 VectorCtrl) cells at 10⁶ cells/mouse were injected intravenously into the tail vein of 8-week old NOD-SCID IL2Rγnull mice (n = 10/group). A: Representative radiographs from a mouse in each group at 28 days after injection. Arrows indicate osteolytic “metastatic” lesion. B: Osteolytic bone lesions in the spine, femur, tibia and ulna bones of each mouse were counted using the radiographs. Although both SBC-5 miR-335+ and SBC-5 miR-29a+ xenografts induced fewer osteolytic lesions than controls, the reduction was significant only in miR-335+ xenografts. C. Frequency distribution of osteolytic lesions revealed that no lesions developed from 3 SBC-5 miR-335+ xenografts, and the remaining 7 SBC-5 miR-335+ mice exhibited fewer lesions than controls. The number of osteolytic lesions from SBC-5 miR-29a+ xenografts did not differ significantly from control. (Compared to control, **: P<0.01).

Figure 4. SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-1R expression. Serum-starved SBC-5 cell lines (SBC-5 miR-335+, SBC-5 miR-29a+ and SBC-5 VectorCtrl) and SBC-3 cells were lysed in RIPA buffer, and IGF-1R expression was studied by Western blotting. Compared to SBC-5 VectorCtrl, IGF-1R expression was lower in SBC-5 miR-335+ and SBC-3 cells, and did not show difference between SBC-5 VectorCtrl and SBC-5 miR-29a+.

Figure 5. miR-335 targeted RANKL and reduced osteoclast induction in SBC-5. Osteoclasts were induced from murine spleen cells using conditioned medium (CM) from
each of the SBC-5 cell lines (SBC-5 Vector<sup>C</sup>ctrl, SBC-5 miR-335<sup>+</sup> and SBC-5 miR-29a<sup>+</sup>) and cell-free unconditioned medium (UM). A: Representative osteoclast induction from each group at 7 days after incubation with CM or UM. B: SBC-5 Vector<sup>C</sup>ctrl CM induced more osteoclast formation compared to cell-free UM. Osteoclast number was significantly decreased in SBC-5 miR-335<sup>+</sup> and in SBC-5 miR-29a<sup>+</sup> compared to SBC-5 Vector<sup>C</sup>ctrl CM (\(* P<0.05, *** P<0.001; n=6/group, 2 replicate experiments\)). C: RANKL expression was evaluated in cell lysates and in culture media by Western-blotting. RANKL expression was lower in SBC-5 miR-335<sup>+</sup> and in SBC-3 compared to SBC-5 Vector<sup>C</sup>ctrl and SBC-5 miR-29a<sup>+</sup>. D: The 3’ UTR of the RANKL gene was analyzed by TargetScan and a target sequence for miR-335 was identified. The strategy to make point mutations within the target sequence was listed as RANKL-3’UTRm. E: The miR-335 precursor gene or the control sequence was stably transfected into 293TN cells by lentivirus. These cells were further co-transfected with pMIR reporter vector inserted with RANKL 3’UTR or RANKL 3’UTRm and the pMIR-REPORT™ beta-galactosidase reporter control vector. The Dual Luciferase Assay kit was used in the 3’UTR reporter assay. Over-expression of miR-335 significantly reduced luciferase activity only in cells containing the RANKL 3’UTR, but not in the cells with mutated seed sequence (RANKL 3’ UTRm). These results indicated that RANKL 3’ UTR was directly targeted by miR-335. (Compared to control, ***: P<0.001; n=3/group, 2 replicate experiments).
Fig. 3

A  SBC-5 Vector\textsuperscript{Ctrl}  SBC-5 miR-335\textsuperscript{+}  SBC-5 miR-29a\textsuperscript{+}

B  Bone metastasis

C  No. Mice with osteolytic lesions

- Average bone lesions in each mouse
- No. Mice with osteolytic lesions
Fig. 4

Vector ctrl

miR-335+  miR-29a+

IGF1R

β-actin

SBC-3

SBC-5

SBC-5

SBC-5

miR-335-

miR-29a−
Fig. 5

A.

B.

C.

D.

E.

---

**Fig. 5**

(A) Representative images of osteoclasts from different cell conditions. Vector CM, miR-335* CM, miR-29a* CM, and Cell-free UM.

(B) Graph showing the average number of osteoclasts per well for different conditions: Vector CM, miR-335* CM, miR-29a* CM, and Cell-free UM. The graph includes error bars for each condition.

(C) Western blot images showing RANKL in cell lysate and β-actin. The band intensities are indicated with asterisks (*). Secreted RANKL in culture medium is also shown.

(D) Diagram illustrating the miR-335 and RANKL-3'UTR sequences. The miR-335 sequence is shown, along with the RANKL-3'UTR and RANKL-3'UTRm sequences.

(E) Graph showing relative luciferase activity for different conditions: 293TN-control and 293TN-miR335. The graph includes error bars for each condition. The luciferase activity is measured in arbitrary units (AU).
miRNA profiles in human SBC-5 and SBC-3 were performed by using the miRNA microarrays (833 human miRNAs). Four replicates of each cell line were analyzed in each microarray. Compared to SBC-3 cells, 14 miRNAs in SBC-5 cells were decreased by more than 2-fold (p<0.001).
Molecular Cancer Research

miR-335 Inhibits Small Cell Lung Cancer Bone Metastases via IGF-1R and RANKL Pathways

Meng Gong, Junrong Ma, Ryan Guillemette, et al.

Mol Cancer Res Published OnlineFirst August 21, 2013.

Updated version
Access the most recent version of this article at:
doi:10.1158/1541-7786.MCR-13-0136

Supplementary Material
Access the most recent supplemental material at:
http://mcr.aacrjournals.org/content/suppl/2013/09/05/1541-7786.MCR-13-0136.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.